Skip to main content

Table 3 Activity of fotemustine in relation to group of dose and histotype

From: Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation

  Group A, no. pts (%) (histotype) Group B, no. pts (%) (histotype) Group C, no. pts (%) (histotype)
Partial Response 2 (40%)
(2 AA)
4 (26.5%)
(1 GBM, 3 AOD)
2 (10%)
(1 AA, 1 AOD)
Stable Disease 2 (40%)
(1 GBM, 1 AA)
4 (26.5%)
(1 GBM, 2 AA, 1 AOD)
5 (25%)
(2 GBM, 1 AA, 2 AOA)
Progression 1 (20%)
(1 GBM)
7 (47%)
(2 GBM, 2 AA, 3 AOA)
13 (65%)
(6 GBM, 2 AA, 2 AOA, 3 AOD)
Total pts 5 15 20
Total GBM 2/5 (40%) 4/15 (26.5%) 8/20 (40%)
  1. AA, anaplastic astrocytoma; AOA, anaplastic oligoastrocytoma, AOD, anaplastic oligodendroglioma; GBM, glioblastoma multiforme; no., number; pts, patients